Everything you need to know about GLP-1s, Medicare coverage

A new federal program now offers Medicare beneficiaries access to GLP-1 weight loss medications. Launched on July 1, the Medicare GLP-1 Bridge program aims to provide coverage for these drugs, which were previously excluded from the federal health insurance system. This development represents a shift in how Medicare manages weight management treatments for older adults.

To qualify for this program, individuals must be enrolled in a Medicare Part D prescription drug plan and meet specific body mass index criteria. The program requires patients to use these medications alongside structured nutrition and physical activity plans. It also mandates that a doctor or licensed prescriber provides a formal prescription, subject to prior authorization reviews. Those who meet the requirements can access the drugs with a monthly copay set at $50.

While this initiative increases accessibility for many people, it is specifically designed for beneficiaries seeking these drugs for weight reduction or weight maintenance. Coverage for other indications such as Type 2 diabetes or sleep apnea remains separate from this pilot. Participants should be aware that the bridge program currently has a set duration, scheduled to run through the end of 2027.

This pilot arrives as demand for weight loss drugs continues to rise, despite high list prices that often exceed $1,000. Data from health policy research indicates that many patients have struggled with the affordability of these treatments. While manufacturers have introduced price reductions for cash-paying customers, this new Medicare pathway offers a structured approach for eligible enrollees to secure the medication under their existing health coverage.